文献速递眼整形与眼眶神经眼科

泪腺癌局部复发与生存预后因素及局部治疗对生存的影响

Prognostic factors for local recurrence and survival and impact of local treatments on survival in lacrimal gland carcinoma.
PubMed 文献 · Br J Ophthalmol · 2020-07-17

该回顾性研究纳入1998年至2018年连续55例泪腺癌患者,评估局部复发、远处转移和疾病特异性生存(DSS)的预后因素。结果显示眶内容物剜除与保留眼球手术在复发风险上无显著差异,保留眼球手术与更好的DSS相关;神经周围侵犯是局部复发的危险因素,腺样囊性癌基底样/实体亚型与更差DSS相关。

要点

  • 眶内容物剜除与保留眼球手术在局部复发、远处转移和DSS风险上无显著差异。
  • 神经周围侵犯与更差的局部无复发生存相关(p=0.02)。
  • 腺样囊性癌基底样/实体亚型患者DSS显著更差(p<0.01)。

核心结论

  • 对于泪腺癌,眶内容物剜除联合辅助治疗与保留眼球手术联合辅助治疗具有相似的复发结局。
  • 保留眼球手术与更好的疾病特异性生存相关。
  • 神经周围侵犯是局部复发的危险因素,腺样囊性癌基底样/实体亚型与更差DSS相关。

研究设计与样本

  • 采用对数秩检验和单因素Cox比例风险回归模型分析危险因素与生存。

主要发现

  • 55例患者中位年龄46岁(范围10-76岁),43例(78%)为腺样囊性癌,31例(56%)初诊时为T2期。
  • 28例(51%)接受眶内容物剜除伴或不伴辅助放疗或放化疗,26例(47%)接受保留眼球手术伴或不伴辅助放疗或放化疗,1例接受姑息性放化疗。
  • 11例(22%)出现局部复发,14例(29%)出现远处转移。
  • 5年和10年局部无复发生存率分别为0.71(95%CI 0.58-0.88);5年和10年无远处转移生存率分别为0.67(95%CI 0.53-0.85)和0.49(95%CI 0.30-0.81)。
  • 腺样囊性癌患者中,眶内容物剜除与保留眼球手术在局部复发、远处转移或DSS风险上无显著差异。

关键数值与推荐

  • 神经周围侵犯与局部无复发生存负相关(p=0.02)。
  • 腺样囊性癌中基底样/实体组织学类型与非基底样/实体类型相比DSS显著更差(p<0.01)。

临床怎么用

  • 泪腺癌治疗决策中,保留眼球手术联合辅助治疗可作为眶内容物剜除的替代选择,两者复发结局相似。
  • 对存在神经周围侵犯的患者应加强局部复发监测。
  • 腺样囊性癌基底样/实体亚型患者预后更差,需更密切随访和个体化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To identify prognostic factors for local recurrence, distant metastasis and disease-specific survival (DSS) for lacrimal gland carcinoma. METHODS: All consecutive patients with lacrimal gland carcinoma treated from January 1998 through December 2018 were included. Log-rank tests and univariate Cox proportional hazards regression models were used to study risk factors and survival. RESULTS: Overall, 55 patients were included in this study, and 5 patients were excluded from the survival analysis. Median age was 46 years (range: 10-76). 43 patients (78%) had adenoid cystic carcinoma (ACC). 31 patients (56%) had T2 disease at presentation. 28 patients (51%) underwent orbital exenteration with or without adjuvant radiotherapy or chemoradiation, 26 (47%) underwent eye-sparing surgery with or without adjuvant radiotherapy or chemoradiation, and 1 received palliative chemoradiation. 11 patients (22%) experienced local recurrence; 14 (29%) experienced distant metastasis. Five- and 10-year local-recurrence-free survival rates were 0.71 (95% CI 0.58 to 0.88), and 5- and 10-year distant-metastasis-free survival rates were 0.67 (95% CI 0.53 to 0.85) and 0.49 (95% CI 0.30 to 0.81), respectively. There was no significant difference in risks of local recurrence, distant metastasis or DSS between ACC patients who had orbital exenteration and those who had eye-sparing surgery. Perineural invasion was negatively associated with local-recurrence-free survival (p=0.02). Among patients with ACC, basaloid/solid histologic type was associated with significantly worse DSS than non-basaloid/solid histologic type (p<0.01). CONCLUSIONS: For lacrimal gland carcinoma, orbital exenteration with adjuvant therapy and eye-sparing surgery with adjuvant therapy are associated with similar recurrence outcomes. Eye-sparing surgery is associated with better DSS. Perineural invasion is a risk factor for local recurrence. ACC with basaloid/solid subtype correlates with worse DSS.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ford JR, Rubin ML, Frank SJ, et al. Prognostic factors for local recurrence and survival and impact of local treatments on survival in lacrimal gland carcinoma. Br J Ophthalmol. 2020. PMID: 32680839. doi:10.1136/bjophthalmol-2020-316142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。